Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), can be used as second-line treatment for lung cancer patients harboring the T790M substitution. Although osimertinib is more effective than the first-generation EGFR-TKIs used for fir...

全面介紹

Na minha lista:
書目詳細資料
發表在:BMC Cancer
Main Authors: Takeda, Yuichiro, Naka, Go, Yamaguchi, Yoh, Hashimoto, Masao, Suzuki, Manabu, Izumi, Shinyu, Sugiyama, Haruhito
格式: Artigo
語言:Inglês
出版: BioMed Central 2020
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7531095/
https://ncbi.nlm.nih.gov/pubmed/33008313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07424-w
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍